Status In progress
Process MTA
ID number 854

Provisional Schedule

Expected publication July 2017

Project Team

Project lead Jeremy Powell

Email enquiries


Companies sponsors AbbVie (adalimumab)
  Pfizer (etanercept)
  Janssen (ustekinumab)
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups Psoriasis Association
  Psoriasis and Psoriatic Arthritis Alliance
Professional groups British Association of Dermatologists
  British Society for Rheumatology
  Royal College of Paediatrics & Child Health
  Royal College of Pathologists
  Royal College of Physicians


Associated public health groups none
Comparator companies Accord Healthcare (methotrexate) (not participating)
  AMCo (methotrexate) (not participating)
  Dexcel Pharma (ciclosporin) (not participating)
  Hospira UK (infliximab, methotrexate) (not participating)
  Merck Sharp & Dohme (infliximab) (not participating)
  Napp Pharmaceuticals (infliximab) (not participating)
  Novartis (ciclosporin)
  Orion Pharma (methotrexate) (not participating)
  Rosemont Pharmaceuticals (methotrexate) (not participating)
  Sandoz (methotrexate) (not participating)
  Santen UK (ciclosporin) (not participating)
General commentators British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
Relevant research groups none


Key events during the development of the guidance:

Date Update
20 April 2017 Committee meeting: 2
17 March 2017 - 07 April 2017 Appraisal consultation
22 February 2017 Committee meeting: 1
06 January 2017 Assessment report sent for information
31 May 2016 Invitation to participate
27 November 2015 Draft scope documents
04 November 2015 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance